CCR5-modified CD4+ T Cells for HIV Infection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 12, 2019

Primary Completion Date

January 31, 2024

Study Completion Date

February 28, 2024

Conditions
HIV Infections
Interventions
BIOLOGICAL

SB-728-T

Autologous CD4+ T cells with ex vivo modification of the CCR5 gene by zinc finger nucleases

BIOLOGICAL

Expanded unmodified autologous CD4+ T cells

Autologous CD4+ T cells without ex vivo modification of the CCR5 gene by zinc finger nucleases

Trial Locations (1)

45267

University of Cincinnati, Cincinnati

All Listed Sponsors
collaborator

University of California, San Francisco

OTHER

collaborator

Case Western Reserve University

OTHER

lead

University of Cincinnati

OTHER

NCT03666871 - CCR5-modified CD4+ T Cells for HIV Infection | Biotech Hunter | Biotech Hunter